NON-SMALL CELL LUNG CANCER (NSCLC)

This study is testing whether using two targeted cancer drugs together works better than standard treatments for people with advanced non-small cell lung cancer that has specific genetic mutations. The trial will involve about 60 adults who haven't had previous treatment for thei…

This study is observing how well the drug brigatinib works for Chinese adults with a specific type of advanced lung cancer (ALK-positive NSCLC) in real-world medical settings. Researchers are not giving any new treatment; they are collecting data from about 200 patients who are a…

This study is testing three new experimental immunotherapy drugs, each combined with an existing immunotherapy called cemiplimab, for adults with advanced non-small cell lung cancer who haven't had prior treatment. The goal is to see if these combinations are safe and can help co…

This is the first human study testing the safety of an experimental drug called AB598 in people with advanced cancers. The trial will enroll 40 participants with various cancers including lung, stomach, bladder, and breast cancer to determine safe dosage levels and monitor side e…

This study is testing whether combining two existing drugs—alirocumab and cemiplimab—can help control advanced lung cancer that has gotten worse after initial immunotherapy. It will involve about 60 adults whose cancer has spread and who have already tried and stopped responding …

This study is testing an experimental virus therapy called RP1, both alone and combined with an immunotherapy drug (nivolumab), for people with advanced solid tumors that have stopped responding to standard treatments. The trial aims to find the safest and most effective dose whi…

This early-stage study is testing a new oral medication called IMM-1-104 in people with advanced solid tumors that have spread. The main goals are to find a safe dose and see if the drug can shrink tumors in cancers like pancreatic, melanoma, and lung cancer. The drug is being te…

This study is testing whether adding a pill called olaparib to an existing immunotherapy drug (durvalumab) works better than the immunotherapy alone to keep advanced lung cancer from getting worse. It involves patients whose cancer has not progressed after initial chemotherapy. T…

This program provides compassionate access to the immunotherapy drug cemiplimab for patients with advanced non-small cell lung cancer, basal cell carcinoma, or cutaneous squamous cell carcinoma. It's designed for individuals who have exhausted all other approved treatment options…

This study tests whether adding a wearable device that creates low-intensity electric fields around the body can help immunotherapy work better for people with advanced lung cancer. It's for patients whose cancer has continued to grow despite previous treatments including immunot…

This study is testing a new drug called U3-1402 (HER3-DXd) for people with advanced non-small cell lung cancer that has spread or cannot be removed by surgery. The main goals are to find a safe dose and see if the drug can shrink tumors in patients whose cancer has worsened despi…

This study is testing if adding a precise, high-dose radiation treatment to a standard targeted drug can help people with advanced lung cancer live longer without their cancer getting worse. It focuses on patients whose cancer has a specific genetic change (EGFR mutation) and who…

This early-stage trial is testing a new antibody drug called GEN1042 to see if it's safe and can help control advanced solid tumors. Researchers are giving GEN1042 alone or combined with another cancer drug (pembrolizumab) to about 350 adults with cancers like lung, colorectal, m…

This early-stage study is testing a new type of personalized cell therapy for people with advanced colorectal, pancreatic, or non-small cell lung cancer. The therapy involves collecting a patient's own immune cells, genetically modifying them to target a specific cancer-causing m…

This early-stage study is testing an experimental drug called furmonertinib for people with advanced lung cancer that has specific genetic mutations. The trial aims to find the safest and most effective dose while checking if the drug can shrink tumors. It involves 160 patients w…

This large, late-stage study tested whether adding one or two immunotherapy drugs (durvalumab and tremelimumab) to standard chemotherapy works better than chemotherapy alone for people newly diagnosed with advanced non-small cell lung cancer that has spread. It involved over 1,10…

This study aims to find out if having a lab technician check tissue samples during a lung biopsy procedure helps doctors collect better quality material for advanced genetic testing. Researchers are comparing the standard biopsy method to one where a technician provides real-time…

This study aims to understand how two new experimental drugs travel to and gather in tumors in people with advanced head and neck cancer, lung cancer, or melanoma. Participants receive one of the new drugs along with an existing immunotherapy, and doctors use special PET scans to…

This study follows 160 lung cancer patients to understand how changes in muscle mass, strength, and function affect their ability to complete treatment, quality of life, and survival. Researchers will measure these factors during routine hospital visits without changing standard …

This study is collecting information from about 400 patients in Italy who are already receiving a specific two-drug immunotherapy combination (nivolumab plus ipilimumab) as their first treatment for advanced or returning non-small cell lung cancer. The goal is to understand how w…

This study looks back at medical records to understand the side effects and healthcare needs of 300 people with advanced lung cancer who have low levels of a specific protein (PD-L1). It examines patients who received various first-line immunotherapy treatments to see how common …